(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in ...

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

In this wide and deep sector, though, there are some notable exceptions. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical ...

In a regulatory filing, AbbVie (ABBV) disclosed that reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

In the closing of the recent trading day, AbbVie (ABBV) stood at $201.64, denoting a -1.73% change from the preceding trading day.

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) dropped 0.2% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $204.55 and last traded at $204.69.

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

April 3 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone ...